Adults who start Gazyva for primary membranous nephropathy will receive four 1,000-milligram intravenous infusions over about six months, according to the drug's updated prescribing information. The schedule calls for an initial infusion, a second at week 2, and two more at weeks 24 and 26.
The label, which followed the Food and Drug Administration's Nov. 13 approval, covers adults with the autoimmune kidney disease who are "at risk of disease progression." Patients are tested for hepatitis B before starting, avoid live vaccines during treatment, and, if they can become pregnant, use birth control during treatment and for six months after the last infusion, WebMD reported.